United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough

UNITED THERAPEUTICS Corp

2025-Q3 EPS reported $20.17 revenue$2,392,500,000

Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.
Tyvaso DPI sales $336.2M (+22% YoY) driving total Tyvaso growth to $478M (+10%).
Orenitram $131.1M (+16%); Unituxin $47.9M (-22%) offset by price increases.
TETON-2 study in IPF shows breakthrough results; could significantly broaden therapeutic reach.
Entered $1B accelerated share repurchase in Aug 2025; received 2.6M shares in Q3 (combined $2B since Mar 2024).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.